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Abstract
Background: Though not common, maxillofacial 
osteosarcomas present a unique challenge in manage-
ment due to a multitude of factors, such as difficulty 
in diagnosis and local complex anatomy, making 
surgical excision difficult as well as debate necessary 
on the usefulness of adjunct treatment modalities, 
such as chemotherapy and radiotherapy. Nonetheless, 
osteosarcomas are a significant health burden because 
of their high morbidity and mortality. Method: 
Retrospective cross-sectional study of records archived 
in the School of Dental Sciences, University of Nairobi. 
Results: 25 cases of maxillofacial sarcomas were seen 
over 26 years. Mean age of occurrence was 35.68 years 
with a preponderance for females (17 cases). The 
mandible was the most affected site, accounting for 18 
cases. Discussion: The management of maxillofacial 
sarcomas in our setting presents significant challenges 
arising from multiple factors such as lack of standardised 
treatment protocol, late presentation of patients, 
diagnostic challenges and loss to follow-up.
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Introduction
With an incidence of 1:100,000 (1,2), osteosarcoma 
is the most common primary neoplasm of bone. Most 
head and neck sarcomas are of the soft tissue type with 
only 20% being of bony or cartilaginous origin (3). In 
the USA, it is estimated that less than 4% of all recorded 
osteogenic sarcomas occur in the jaw (4). The mandible 
and maxilla are the predominant sites of head and neck 
osteosarcoma (HNOS), although extragnathic bone as 
well as soft tissue sites may be affected [6]. The 5-year 
disease-specific survival rate for patients with HNOS 
has been poor with most studies reporting survival rates 
of 23–37%, with maxillary tumours showing worse 
prognosis (5-8). Maxillofacial sarcomas have a biological 
behaviour that differs from that of the long bones: 
the average age of onset is 10–20 years later than their 
skeletal variants, distant metastases are rarer and survival 
rates are more favourable (9). The mainstay of treatment 
for osteosarcoma of the jaws is complete surgical 
excision with free margins as well as reconstruction to 
improve function and quality of life post-treatment. 
The use of multidrug chemotherapy (both neoadjuvant 
and adjuvant) in the management of skeletal OS is well 
established with notable improvements in survival rates, 
but the same cannot be said for OS in the maxillofacial 
region. Two meta analyses reviewing the outcomes of 
adding chemotherapy regimes in head and neck OS 
showed conflicting results (10). Nonetheless, several 
individual centre reports have shown a benefit with the 
addition of neoadjuvant or adjuvant chemotherapy, or 
both (11). In the maxillofacial region, extensive lesions 
may provide a challenge where the complex local 
anatomy and proximity to vital structures may preclude 
wide excision with adequate tumour-free margins. 
This paper reviews 25 cases of OS seen over 26 years in 
one specialized department in a teaching institution.
Materials and Methods
The study was conducted at the Department of Oral 
and Maxillofacial Surgery, School of Dental Sciences, 
University of Nairobi, using patient clinical and 
histopathologic records archived at the department. 
This was a retrospective cross-sectional study analysing 
all the records of patients who had a histologic diagnosis 
of maxillofacial OS. Patient clinical and histopathologic 
records were retrieved and data recorded in a data 
collection form. Incomplete patient records were 
excluded from the study. Ethical approval was obtained 
from the Ethics, Research and Standards Committee of 
the Kenyatta National Hospital and the University of 
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Nairobi (approval number: P170/6/2009).
Results
Twenty-five cases were analysed, and women were more 
affected (17 cases) than men (8 cases). The mandible 
was the most common site afflicted (18 cases) while 
7 cases were in the maxilla. The age range was from 1 
week old to 70 years; 15 patients were below the age of 
39 years. The mean age of occurrence was 35.68 years. 
Table 1 shows the distribution of cases by age.
Table 1. Distribution of cases by age
Age group (years) Osteosarcoma cases
0–9 1
10–19 4
20–29 6
30–39 4
40–49 3
50–59 3
>60 4
The histopathologic subtypes varied between 
osteoblastic, fibroblastic and chondroblastic high-
grade variants. One patient was diagnosed with an 
aggressive telangiectatic/ vascular type of osteosarcoma 
while another had a discordant diagnosis: initial 
histological diagnosis was osteoblastoma, later revised 
to osteosarcoma after review by a panel of pathologists.
Musculoskeletal Tumour Society Cancer Centre staging 
was noted for 20 patients only who were in the surgery 
and chemotherapy group and the palliative chemo-
radiotherapy group (3). The patients were all in stage 
II. No staging was noted for five patients who had been 
treated earlier in this series with either surgery alone or 
surgery and radiotherapy. No details were noted from 
the clinical records of why these patients were offered 
these treatment modalities. 
Over the past 26 years, the modalities of management 
have mainly been multimodal therapy involving 
neoadjuvant chemotherapy, then cytoreduction therapy 
followed by postoperative adjuvant chemotherapy 
(Table 2).
Table 2. Treatment modalities and outcomes
Treatment modality
No. of 
patients Outcome
Surgery alone 4
Unknown–All lost to 
follow-up posttreatment
Surgery + 
chemotherapy 
(neoadjuvant and 
adjuvant) 13
5 patients still on follow-
up 10 years. Stable 
posttreatment
Surgery + 
radiotherapy 1
Unknown–Lost to 
follow-up posttreatment
Palliative chemo-
radiotherapy 7 All deceased
Case – Mandibular osteosarcoma
Patient MM, a 54-year-old female, was referred with a 
swelling of the right side of the mandible of one month 
duration (Fig. 1). She had impaired sensation of the right 
inferior alveolar nerve. There was no significant medical 
history apart from hyperacidity related to non-steroidal 
anti-inflammatory drugs. 
A CT scan revealed a lytic soft tissue mass arising from 
the right mandibular alveolus and extending to the 
surrounding soft tissues (Fig. 2).
Histopathology sections (Fig. 3) showed features of 
osteoblastic type (high grade) osteosarcoma.
High-resolution chest CT scan (Fig. 4) confirmed there 
was no metastasis of the tumor to the chest.
Management protocol for the patient included 
multimodal treatment as follows:
•	 neoadjuvant chemotherapy–3 cycles
•	 surgery (postchemotherapy) and initial primary 
reconstruction–tumour specimen was resected 
enbloc and reconstructed with a 2.5 mm preformed 
titanium plate and soft tissue (cheek and floor 
of mouth) augmentation with a pectoralis major 
Figure 2. Left, CT scan – axial view; right, coronal view. The 
mass is marked in green arrows.
Figure 1. Above, 
extraoral appearance; 
right, intraoral 
appearance
at presentation.
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pedicled flap (Fig. 5).
•	 postoperative chemotherapy–4 cycles after 6 
weeks postoperative (Fig. 6).
Discussion
Generally, maxillofacial mesenchymal malignancies are 
rare. In the present study, 25 maxillofacial osteosarcomas 
were noted over 26 years. Some trends were noted in the 
demographic distribution of the maxillofacial sarcomas. 
In our study, the most frequent site of occurrence was 
the mandible, which concurs with most of the reports 
in literature (1,3). Analysis of age distribution of 
maxillofacial osteosarcomas in this study showed that 
the mean ages at first presentation of maxillofacial 
osteosarcoma was consistent with data from other 
African studies (12).
The lower mean age of occurrence of osteosarcoma 
is probably influenced by the lower age expectancy 
in the Kenyan population (52 years in 2006) (12). 
Gender distribution showed a female 
preponderance, in contrast to literature 
which did not note any real preference for 
any gender (1,2,12).
The management of osteosarcoma 
remains a challenge. First, these tumours 
remain relatively rare and may be 
considered as “orphan diseases” (13). 
In our case series we encountered 25 
cases over 26 years. Second, they remain 
a challenge to diagnose. Our series did 
have a case that was initially diagnosed as 
an osteoblastoma. The clinical behaviour 
of the lesion did not correspond with 
the histological examination. Tissue 
specimen was re-evaluated and a diagnosis 
of osteosarcoma was made. Finally, 
management of the tumours presents 
challenges due not only to their aggressive 
nature but also to a lack of consensus on 
the mode of management. Literature 
on the management of maxillofacial 
Figure 3. Histopathology specimen.
Figure 4. High resolution chest CT scan.
Figure 5.Clockwise: Titanium reconstruction plate, pectoralis major flap with 
skin paddle for intraoral closure, immediate postoperative, tumour specimen 
after resection.
guthua et al.
Figure 6. Left, extra oral appearance; right, intraoral appearance. 
Note the pectoralis major skin paddle (arrow).
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sarcomas is scarce, and the little that is available does 
not provide consensus on the treatment protocol. 
While aggressive surgical extirpation is necessary, the 
use of chemotherapy in maxillofacial osteosarcomas 
remains controversial (5,10). The use of chemotherapy 
in managing appendicular (long bone) osteosarcoma is 
well proven, but evidence is conflicting on its use in the 
head and neck (11). Nevertheless, it appears the use of 
chemotherapy has some advantage over surgery alone 
(4). Radiotherapy is not as effective as chemotherapy 
as osteosarcomas have been shown to be radio-resistant. 
The five patients in this study who remained disease 
free for 10 years had gone through a management 
approach involving neoadjuvant chemotherapy (3 
cycles), followed by complete surgical extirpation and 
then adjuvant chemotherapy (4 cycles). From our case 
series, the overall outcomes were relatively poor with all 
patients presenting in stage III and this may have been 
attributed to late presentation of patients with these 
aggressive lesions. A challenge still remains of patient 
follow-up in our setting. Of the 25 cases in our case 
series, 12 patients were lost to follow-up possibly due to 
socio-economic factors, 7 patients were deceased and 5 
patients are still on follow-up (10-year median time).
Management of sarcomas remains a challenge 
essentially because these cancers are rare, they are 
biologically diverse and difficult to diagnose, a large 
multicentre evidence base for treatment is lacking, 
treatment regimens are complex and intense, and they 
have a high mortality. The National Cancer Control 
Network (US) and the National Institute for Health 
and Clinical Excellence (UK) have developed detailed 
recommendations limiting management of sarcomas to 
MDT sarcoma teams with specialist sarcoma experts—
surgeons, pathologists, radiologists, oncologists—as 
well as support staff (14). 
Conclusion
The management of jaw sarcomas in Kenya remains a 
challenge. Possibly, embracing the sarcoma centre model 
would improve outcomes by concentrating patient 
load and expertise in these centres with the attendant 
advantages of long-term follow-up and development of 
evidence-based treatment protocols.    
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